JP2007507422A - テトロドトキシンの安定な凍結乾燥医薬製剤 - Google Patents

テトロドトキシンの安定な凍結乾燥医薬製剤 Download PDF

Info

Publication number
JP2007507422A
JP2007507422A JP2006519747A JP2006519747A JP2007507422A JP 2007507422 A JP2007507422 A JP 2007507422A JP 2006519747 A JP2006519747 A JP 2006519747A JP 2006519747 A JP2006519747 A JP 2006519747A JP 2007507422 A JP2007507422 A JP 2007507422A
Authority
JP
Japan
Prior art keywords
tetrodotoxin
formulation
content
solution
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006519747A
Other languages
English (en)
Japanese (ja)
Inventor
シァオ ザン
ユーホン カン
シァオヤン フアン
Original Assignee
ナンニン メイプル リーフ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナンニン メイプル リーフ ファーマシューティカル カンパニー リミテッド filed Critical ナンニン メイプル リーフ ファーマシューティカル カンパニー リミテッド
Publication of JP2007507422A publication Critical patent/JP2007507422A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2006519747A 2003-07-14 2004-07-02 テトロドトキシンの安定な凍結乾燥医薬製剤 Pending JP2007507422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA031460208A CN1568999A (zh) 2003-07-14 2003-07-14 稳定的医药用河豚毒素冷冻干燥制剂
PCT/CN2004/000736 WO2005004874A1 (fr) 2003-07-14 2004-07-02 Preparation medicinale lyophilisee stable contenant de la tetrodotoxine

Publications (1)

Publication Number Publication Date
JP2007507422A true JP2007507422A (ja) 2007-03-29

Family

ID=33752652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519747A Pending JP2007507422A (ja) 2003-07-14 2004-07-02 テトロドトキシンの安定な凍結乾燥医薬製剤

Country Status (10)

Country Link
US (3) US8124608B2 (fr)
EP (1) EP1645277A4 (fr)
JP (1) JP2007507422A (fr)
KR (1) KR20060096411A (fr)
CN (2) CN1568999A (fr)
BR (1) BRPI0412002A (fr)
CA (1) CA2529598C (fr)
MX (1) MXPA06000243A (fr)
WO (1) WO2005004874A1 (fr)
ZA (1) ZA200510106B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502932A (ja) * 2008-09-17 2012-02-02 厦門朝陽生物工程有限公司 フグ毒の凍結乾燥注射用粉末製剤及びその製造法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
GT200600112A (es) 2005-03-14 2006-11-29 Composiciiones de tigeciclina y metodos de preparacion
WO2007025213A2 (fr) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Utilisation de bloqueurs des canaux sodiques pour gerer les douleurs musculo-squelettiques
EP1928452A4 (fr) * 2005-08-25 2010-09-01 Wex Medical Ltd Utilisation de bloqueurs des canaux sodiques pour traiter les douleurs viscerales, ou les douleurs provoquees par un traitement anticancereux
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN103271920A (zh) * 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
CN101239061B (zh) * 2006-10-18 2011-05-11 江苏宏锦天药业有限公司 氨基全氢化喹唑啉类化合物清除生物体内瘦肉精的用途
WO2008088174A1 (fr) * 2007-01-19 2008-07-24 Sang Gil Lee Composition comprenant des extraits de poisson-globe préparés à l'aide d'une protéase et son procédé de fabrication
CN101450056B (zh) * 2007-12-06 2013-04-24 江苏宏锦天药业有限公司 钠离子通道阻断剂用于治疗抗生素对生物耐药性的新用途
CN101554368B (zh) * 2008-04-07 2013-06-12 江苏宏锦天药业有限公司 一种室温稳定的注射用替曲朵辛组合物制剂
CN102020653A (zh) * 2009-09-22 2011-04-20 江苏宏锦天药业有限公司 氨基全氢化喹唑啉类化合物及其衍生物制备提高抗癌药药效的新应用
IN2013MU01127A (fr) 2013-03-26 2015-05-01 Astron Res Ltd
KR101398764B1 (ko) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 입자의 이동에 의해 분석물질을 검출하는 장치 및 방법
CN111122752B (zh) * 2020-02-26 2022-06-10 浙江清华长三角研究院 一种河豚毒素成分分析标准物质的制备方法
CN112704665A (zh) * 2021-01-08 2021-04-27 江苏宏锦天药业有限公司 替曲朵辛口服制剂、替曲朵辛冻干片及其应用
CN115475151A (zh) * 2022-08-14 2022-12-16 中国人民解放军海军军医大学 河豚毒素缓释微球及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JPH09136836A (ja) * 1995-09-13 1997-05-27 Nippon Shinyaku Co Ltd Ｐｇｅ１含有凍結乾燥製剤及び製法
WO2001093827A2 (fr) * 2000-06-02 2001-12-13 Allergan, Inc. Implant d'administration de neurotoxine
WO2002022129A1 (fr) * 2000-09-18 2002-03-21 Wex Medical Instrumentation Co Methode analgesique
WO2002041915A1 (fr) * 2000-11-22 2002-05-30 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition de compose bloquant les canaux sodiques
CN1385431A (zh) * 2002-06-24 2002-12-18 厦门一元生物工程有限公司 河豚毒素高纯单体规模化制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2912361A (en) * 1956-11-28 1959-11-10 Sterling Drug Inc Canine distemper vaccine and its preparation
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1995024903A1 (fr) * 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
EP0857484A4 (fr) * 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd Preparation lyophilisee contenant de la pge1- et son procede de production
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6326020B1 (en) 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
EP1058547B1 (fr) * 1998-03-03 2005-11-23 Shionogi & Co., Ltd. Compositions pharmaceutiques contenant un 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate sodique, inhibiteur des phospholipases
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1240702C (zh) * 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1187356C (zh) * 2000-11-22 2005-02-02 南宁枫叶药业有限公司 高获得率提取替曲朵辛的系统
CN1187355C (zh) * 2000-11-22 2005-02-02 南宁枫叶药业有限公司 精制高纯度替曲朵辛的方法
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN100360133C (zh) 2002-05-23 2008-01-09 潘心富 用于戒毒、镇痛的河豚毒素呼吸道给药制剂
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20090143415A1 (en) 2004-09-21 2009-06-04 Wex Pharmaceuticals, Inc. Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain
CN101039675A (zh) 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
EP1928452A4 (fr) 2005-08-25 2010-09-01 Wex Medical Ltd Utilisation de bloqueurs des canaux sodiques pour traiter les douleurs viscerales, ou les douleurs provoquees par un traitement anticancereux
CN103271920A (zh) 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JPH09136836A (ja) * 1995-09-13 1997-05-27 Nippon Shinyaku Co Ltd Ｐｇｅ１含有凍結乾燥製剤及び製法
WO2001093827A2 (fr) * 2000-06-02 2001-12-13 Allergan, Inc. Implant d'administration de neurotoxine
WO2002022129A1 (fr) * 2000-09-18 2002-03-21 Wex Medical Instrumentation Co Methode analgesique
WO2002041915A1 (fr) * 2000-11-22 2002-05-30 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition de compose bloquant les canaux sodiques
CN1385431A (zh) * 2002-06-24 2002-12-18 厦门一元生物工程有限公司 河豚毒素高纯单体规模化制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502932A (ja) * 2008-09-17 2012-02-02 厦門朝陽生物工程有限公司 フグ毒の凍結乾燥注射用粉末製剤及びその製造法

Also Published As

Publication number Publication date
ZA200510106B (en) 2009-09-30
KR20060096411A (ko) 2006-09-11
CN1835754A (zh) 2006-09-20
US20050020610A1 (en) 2005-01-27
CN100457110C (zh) 2009-02-04
US20100249150A1 (en) 2010-09-30
WO2005004874A1 (fr) 2005-01-20
US8530481B2 (en) 2013-09-10
US8124608B2 (en) 2012-02-28
BRPI0412002A (pt) 2006-08-15
CA2529598C (fr) 2017-03-07
CA2529598A1 (fr) 2005-01-20
CN1568999A (zh) 2005-01-26
US20120264767A1 (en) 2012-10-18
MXPA06000243A (es) 2006-04-07
EP1645277A4 (fr) 2011-08-17
US8222258B2 (en) 2012-07-17
EP1645277A1 (fr) 2006-04-12

Similar Documents

Publication Publication Date Title
US8530481B2 (en) Stable pharmaceutical composition of freeze-dried tetrodotoxin powder
KR102350489B1 (ko) 안정한 인슐린 분비 촉진 펩티드의 하이드로 인젝션 약제학적 조성물
EP0546018B1 (fr) Composition pharmaceutique de florfenicol
EA028572B1 (ru) Стабильная композиция для парентеральной инъекции и способы ее получения и использования
KR101563308B1 (ko) 피노셈브린과 사이클로덱스트린 또는 그의 유도체와의 포접 화합물
EA036982B1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с
EP2958554B1 (fr) Composition stable de bendamustine
EP2922530B1 (fr) Compositions d'acétate de caspofungine
TR201809354T4 (tr) 5 alfa androstan (alkil) 3 beta,5,6 beta triol enjeksiyonu ve Bunun hazırlanmasına yönelik yöntem.
CN101317846B (zh) 一种用于戒毒、镇痛的河豚毒素制剂
JP6063064B2 (ja) 安定したノカチアシン凍結乾燥製剤
JP2012502932A (ja) フグ毒の凍結乾燥注射用粉末製剤及びその製造法
CN101891751B (zh) 一种河豚毒素的制备方法
US20080312304A1 (en) Topical compositions containing metronidazole
CN104800172A (zh) 注射用卡络磺钠粉针剂和制法
JP2022185009A (ja) 安定したアザシチジン含有医薬組成物の製造方法
CN111789818B (zh) 注射用盐酸罂粟碱药物组合物及制备方法
CN101554368B (zh) 一种室温稳定的注射用替曲朵辛组合物制剂
JP2001163776A (ja) 安定化された液剤
JPH03206040A (ja) 注射用溶液及びその調製方法
EP3795166A1 (fr) Composition pharmaceutique d'agoniste du récepteur kor
US20080287515A1 (en) Topical compositions containing metronidazole
WO2017198224A1 (fr) Composition pharmaceutique de rémimazolam
WO2023173615A1 (fr) Solution aqueuse médicamenteuse à base d'ester de peptide stable
AU2016364380A1 (en) Formulations for intravenous injection of danirixin

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719